Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

Novavax announced that it's COVID-19 vaccine could get full approval from the U.S. Food and Drug Administration soon.The ...

Pfizer's PFE non-COVID operational revenues improved in 2024, driven by its key in-line products like Vyndaqel, Padcev and ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

The company says its vaccine is on track for full approval, following delay. Novavax shares soared following the announcement ...

Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. Read ...

Under emergency use, vaccines can be removed even after a health emergency is considered to be over. Full approval from the ...

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

A team of health experts is launching an independent project that could start its own vaccine evaluation and guidelines — ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...